scispace - formally typeset
J

Julio Benítez

Researcher at University of Extremadura

Publications -  108
Citations -  4483

Julio Benítez is an academic researcher from University of Extremadura. The author has contributed to research in topics: Debrisoquine & Genotype. The author has an hindex of 40, co-authored 108 publications receiving 4357 citations. Previous affiliations of Julio Benítez include University of Illinois at Urbana–Champaign & Hospital Clínico San Carlos.

Papers
More filters
Journal ArticleDOI

CYP2C8*3 Polymorphism and Donor Age are Associated With Allograft Dysfunction in Kidney Transplant Recipients Treated With Calcineurin Inhibitors

TL;DR: The results show that genetic and clinical parameters can be combined to identify risk factors for allograft dysfunction in renal transplant recipients.
Journal ArticleDOI

Modulation of midazolam 1-hydroxylation activity in vitro by neurotransmitters and precursors.

TL;DR: Brain CYP3A activity could be modulated by some neurotransmitters and precursors, corresponding to three different metabolic routes, which comprised serotonergic, catecolaminergic, and GABAergic transmitters and Precursors.
Journal ArticleDOI

GST polymorphisms interact with dietary factors to modulate lung cancer risk: study in a high-incidence area.

TL;DR: The results show that the inverse association observed between the intake of dietary carotenoid-rich vegetables and lung cancer risk is dependent on the GST genotype.
Journal ArticleDOI

CYP2D6 polymorphism is not associated with essential tremor.

TL;DR: Results indicate that mutations at the CYP2D6 gene do not seem to be a major factor in determining susceptibility to ET, and reinforces the view that ET and parkinsonism are distinct conditions.
Journal ArticleDOI

Frequency of S-mephenytoin hydroxylation deficiency in 373 Spanish subjects compared to other Caucasian populations.

TL;DR: The prevalence of poor metabolisers (PM) of S-mephenytoin in 373 unrelated, healthy Spanish Caucasian subjects, based on the enantiomeric S/R mephenytoin ratio in urine collected 0–8 h and 24–32 h after intake of the racemic drug, is investigated.